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Background: Functional exercise capacity in people with asbestos related pleural disease (ARPD) is unknown and
there are no data on health-related quality of life (HRQoL). The primary aims were to determine whether functional
exercise capacity and HRQoL were reduced in people with ARPD. The secondary aim was to determine whether
functional exercise capacity was related to peak exercise capacity, HRQoL, physical activity or respiratory function.
Methods: In participants with ARPD, exercise capacity was measured by the six-minute walk test (6MWT) and
incremental cycle test (ICT); HRQoL by the St George’s Respiratory Questionnaire and physical activity by an activity
monitor worn for one week. Participants also underwent lung function testing.
Results: 25 males completed the study with a mean (SD) age of 71 (6) years, FVC 82 (19)% predicted, FEV1/FVC 66
(11)%, TLC 80 (19)% predicted and DLCO 59 (13)% predicted. Participants had reduced exercise capacity
demonstrated by six-minute walk distance (6MWD) of 76 (11)% predicted and peak work rate of 71 (21)% predicted.
HRQoL was also reduced. The 6MWD correlated with peak work rate (r=0.58, p=0.002), St George’s Respiratory
Questionnaire Total score (r=-0.57, p=0.003), metabolic equivalents from the activity monitor (r=0.45, p<0.05), and
FVC % predicted (r=0.52, p<0.01).
Conclusions: People with ARPD have reduced exercise capacity and HRQoL. The 6MWT may be a useful surrogate
measure of peak exercise capacity and physical activity levels in the absence of cardiopulmonary exercise testing
and activity monitors.
Trial registration: ANZCTR12608000147381
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Asbestos related pleural disease (ARPD) is a worldwide
problem with non-malignant pleural disease a common
manifestation of asbestos exposure. Despite tighter regu-
lations in the use of asbestos in many developed coun-
tries, the legacy of asbestos exposure remains and the
incidence of asbestos-related pleural abnormalities con-
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reproduction in any medium, provided the orAsbestos related pleural disease may result in pleural
fibrosis [1]. Despite being recognized as a separate entity
to pulmonary fibrosis [2], ARPD remains poorly investi-
gated and understood. The ensuing symptoms, such as
shortness of breath on exertion [3,4] are similar to other
chronic respiratory diseases and may cause considerable
functional impairment to the individual. Previous studies
have demonstrated abnormal responses or reductions in
peak exercise capacity during cardiopulmonary exercise
testing [5-7] in people with ARPD. However, no studies
have investigated the effects of ARPD on functional ex-
ercise capacity.
The six-minute walk test (6MWT) is a measure of
functional exercise capacity widely used in the assessmentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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monary disease (COPD) [8]. Evidence is growing for
the value of the 6MWT in evaluating functional
exercise capacity in interstitial lung diseases [9] yet
functional exercise capacity in people with ARPD is
unknown.
The effects of ARPD on health-related quality of life
(HRQoL) have not previously been investigated. Chronic
respiratory diseases are frequently associated with decre-
ments in HRQoL [10]. Furthermore, there are no data
on the effects of ARPD on levels of physical activity.
Levels of physical activity in other lung diseases, such as
COPD, have been linked to health outcomes and
HRQoL [11,12].
The primary aims of this study were to determine
whether functional exercise capacity and HRQoL were
reduced in people with ARPD. The secondary aim was
to determine whether functional exercise capacity was
related to peak exercise capacity, HRQoL, physical activ-
ity or respiratory function.Methods
Subjects
This observational study was conducted at Royal Prince
Alfred Hospital, Sydney, Australia from November 2008
- August 2010. Participants were recruited through the
Workers’ Compensation Dust Diseases Board (DDB) of
New South Wales, respiratory physicians, support
groups, workers’ unions and newsletters for returned
servicemen.
People were eligible to participate if they had a diagno-
sis of ARPD, defined as asbestos-related diffuse pleural
thickening and/ or rounded atelectasis. Diagnosis had
been established by the participant’s respiratory phys-
ician or the DDB Medical Authority, a panel of three
respiratory physicians with specialist knowledge in occu-
pational lung disease. The diagnostic process at the DDB
has previously been described, and includes radiological
investigation, lung function testing, clinical examina-
tion by a thoracic physician and a lifetime occupational
history [13]. Computerised tomography (CT) scans had
been conducted on all participants prior to study
commencement.
People were excluded from the study if they had meso-
thelioma; discrete parietal pleural plaques as their only
manifestation of dust exposure; cardiovascular, neuro-
logical or orthopaedic conditions limiting exercise per-
formance; were on long term oxygen therapy; could not
understand English; or had participated in pulmonary
rehabilitation within the last 12 months.
The study was approved by the Human Research Eth-
ics Committee of Sydney South West Area Health Ser-
vice. All participants gave written informed consent.Pulmonary function tests
Participants performed pulmonary function tests of spir-
ometry, lung volumes (body plethysmography) and sin-
gle breath diffusing capacity for carbon monoxide
(DLCO) (SensorMedics, Yorba Linda, Ca, USA). Tests
were performed according to American Thoracic Society
(ATS) guidelines and results expressed as a percentage
of predicted values [14-16]. Maximal voluntary ventila-
tion (MVV) was calculated as forced expiratory volume
in one second (FEV1) multiplied by 40 [17]. Forced vital
capacity (FVC) and DLCO were the pulmonary function
values used in the correlation analyses.
Exercise testing
Participants performed two 6MWTs (6MWT 1 and
6MWT 2) according to ATS guidelines [18] on a 32-
metre oval track with tests separated by a minimum of
30 minutes. Throughout both tests standardised instruc-
tions and encouragement were given. Each minute pulse
rate (PR) and oxygen saturation (SpO2) were measured
(Radical™, Masimo Corporation, Irvine, USA) and dys-
pnoea and rate of perceived exertion (RPE) scores ran-
ging from 0–10 (0 was ‘nothing at all’ and 10 was
‘maximal’) were recorded [19,20]. The better 6MWT
was used for analysis.
On a second day of testing, participants performed a
symptom-limited incremental cycle test (ICT) to peak
work capacity on an electromagnetically-braked cycle
ergometer (Lode BV, Groningen, The Netherlands). Fol-
lowing two minutes of rest and one minute of unloaded
cycling, work rate was increased every minute by a pre-
determined amount, from 5 to 20 W.min-1 according to
the participant’s self-reported exercise capacity and dis-
ease severity so that the test was approximately 10 min-
utes duration [21]. Breath-by-breath values for oxygen
uptake (VO2) and carbon dioxide output (VCO2) were
obtained (Vmax Encore, SensorMedics, Yorba Linda,
USA). Volume and gas calibration were performed prior
to each test. Pulse rate and SpO2 were simultaneously
measured and dyspnoea and RPE scores were recorded
each minute and at peak work rate. The test was ceased
when the participant reached symptom-limited max-
imum. Results of the 6MWT and ICT were compared to
predicted normal values [22,23].
Health-related quality of life (HRQoL)
Participants completed the St George’s Respiratory
Questionnaire (SGRQ) [24]. A priori, the ‘Activity’ do-
main and ‘Total’ score from the SGRQ were identified to
examine against measures of exercise capacity.
Physical activity
Participants wore an activity monitor (SenseWear Pro3
Armband, BodyMedia, Pittsburgh, PA, USA) for one-
Table 1 Demographic data, pulmonary function and
smoking history
n=25 mean (SD)
Age, yr 71 (6)
Height, cm 174 (5)
Weight, kg 84 (12)
BMI, kg/m2 28 (3)
FVC, % pred 82 (19)
FEV1, % pred 74 (20)
FEV1/FVC % 66 (11)
TLC, % pred 80 (19)
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were instructed to wear the armband continuously, re-
moving it only when showering or swimming. The activ-
ity monitor, worn on the right triceps, incorporated a
biaxial accelerometer and sensors for skin temperature,
heat flux, and galvanic skin resistance. Mean data on
steps per day, the daily metabolic equivalents (METs)
and energy expenditure were recorded. A minimum
compliance of three days of wear with a daily compli-
ance level of 85% was specified for increased measure-
ment accuracy [25]. If this level of compliance was not
achieved, the data or day was excluded from analysis.FRC, % pred 80 (23)
RV, % pred 78 (29)
DLCO, % pred 59 (13)
KCO, % pred 84 (18)
Smoking, pack year 12 (15)
Never smoked (n) 6
n = number; SD = standard deviation; yr = year; cm = centimetre; kg =
kilogram; BMI = body mass index; m = metre; FVC = forced vital capacity; %
pred = percentage of predicted value; FEV1 = forced expiratory volume in one
second; TLC = total lung capacity; FRC = functional residual capacity; RV =
residual volume; DLCO = diffusing capacity for carbon monoxide; KCO =
carbon monoxide transfer coefficient.Statistical analysis
Statistical analysis was performed on PASW-Windows
(release 18.0; PASW, Chicago, IL, USA). Data are
expressed as mean (SD) or (95% CI). A paired-sample t
test was used to compare the distance walked in 6MWT
1 and 6MWT 2, and to compare dyspnoea, PR and RPE
achieved in the better 6MWT with those from the ICT.
Relationships between variables were examined using
Pearson’s correlation coefficients. The level of signifi-
cance was set at a p-value of <0.05.Results
Subjects
Twenty-eight male participants were assessed with 25
included in the study. The reasons for non-inclusion of
three participants were pain affecting exercise perform-
ance (one), neurological impairment (one) and a signifi-
cant degree of emphysema (one). Mean anthropometric
data and pulmonary function are shown in Table 1.Exercise capacity
Participants demonstrated reduced functional exercise
capacity measured by the 6MWT when compared to
predicted values [22] (Table 2). Participants also demon-
strated reduced peak work capacity. The subjective rea-
sons for ceasing the ICT were dyspnoea in eight
participants, leg fatigue in ten participants and com-
bined dyspnoea and leg fatigue in seven participants.Health-related quality of life
Participants demonstrated reduced levels of HRQoL
across all domains of the SGRQ. Mean data are shown
in Table 2.Repeatability of the six-minute walk test
There was a significant mean difference between 6MWT
1 and 6MWT 2 of 13 metres (95% CI: 6 to 21) (p<0.001)
with 80% of participants walking further on 6MWT 2.Responses during the better 6MWT
In the better 6MWT, 44% of participants desaturated by
≥ 4%. There was a significantly greater desaturation dur-
ing the 6MWT compared to the ICT, mean difference
3% (95% CI: 1 to 4), (p<0.001). The PR, RPE and dys-
pnoea responses at the end of the 6MWT were signifi-
cantly lower than at the end of the ICT (Table 3). The
minute-by-minute SpO2 and PR responses during the
6MWT are shown in Figures 1 and 2.
Relationships between functional and peak exercise
capacity
There were significant positive correlations between
6MWD and peak work rate, r=0.58 (p=0.002) and be-
tween 6MWD and VO2 peak (ml/kg/min), r=0.53
(p=0.006).
Physical activity
The activity monitor data was unavailable for two parti-
cipants who did not wear it for the minimum three days
due to skin irritation. Among remaining participants,
the activity monitor was worn for a mean (SD) of 6 (1)
days with a mean compliance of 98 (1)%. Physical activ-
ity data are presented in Table 2.
Relationships of exercise capacity to lung function,
physical activity and health-related quality of life
The 6MWD was significantly correlated with pulmonary
function, physical activity and HRQoL (Table 4).
Table 2 Exercise test results for the 6MWT and the ICT,
health-related quality of life and physical activity data
mean (SD)
6MWT n=25
6MWD, m 486 (68)
6MWD, % pred 76 (11)
Resting SpO2, % 97 (1)
Desaturation, % 4 (3)
Peak PR, % pred* 67 (11)
Dyspnoea at test end 2 (2)
RPE at test end 1 (2)
ICT n=25
Work ratepeak, W 114 (36)
Work ratepeak, % pred 71 (21)
VO2 peak, % pred 83 (22)
VE, L/min 54 (14)
VE/MVV 63 (16)
Resting SpO2, % 99 (1)
Desaturation, % 1 (2)
PR, % pred 82 (13)
Dyspnoea at peak 4 (2)
RPE at peak 5 (2)
HRQoL n=25
SGRQ Symptoms 29 (21)
SGRQ Activity 34 (22)
SGRQ Impacts 15 (14)
SGRQ Total 23 (15)
Physical activity n=23
Average daily steps 9072 (3186)
Average daily METs 1.3 (0.2)
Average daily EE, cal 2630 (459)
SD = standard deviation; 6MWT = six-minute walk test; n = number; 6MWD =
six-minute walk distance; m = metre; % pred = percentage of predicted value;
SpO2 = oxygen saturation; PR = pulse rate; RPE = rate of perceived exertion;
ICT = incremental cycle test; W = watts; VO2peak % pred = percent of
predicted normal maximal oxygen uptake; VE
= minute ventilation; MVV = maximal voluntary ventilation; HRQoL = health-
related quality of life; SGRQ = St George’s Respiratory Questionnaire; METs
= metabolic equivalent; EE = energy expenditure; cal = calorie.
* Predicted PR = 220 – age.
Table 3 Mean difference in end exercise PR, dyspnoea and RP
Variable ICT mean (SD) 6MWT mea
PR, b/min 122 (19) 100 (1
Dyspnoea, score 4 (2) 2 (2)
RPE, score 5 (2) 1 (2)
ICT = incremental cycle test; 6MWT = six-minute walk test; SD = standard deviation;
of perceived exertion.
Figure 1 SpO2 response during the 6MWT. SpO2 = oxygen
saturation; Error bars = Standard error.
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This study examined the effects of ARPD on functional
exercise capacity and HRQoL. The main findings were
people with ARPD had reduced functional exercise cap-
acity and HRQoL, despite only having pleural involve-
ment. In addition, this study showed significant
relationships of functional exercise capacity to peak ex-
ercise capacity, physical activity and HRQoL in people
with ARPD. The relationships demonstrated that a lower
6MWD was significantly associated with a lower peak
work rate, level of physical activity and HRQoL. Such
findings have not been previously demonstrated.
Functional exercise capacity and peak exercise capacity
were reduced compared to predicted values. At peak ex-
ercise, the limiting symptom was leg fatigue in 40% of
participants and dyspnoea in 32% of participants. Leg fa-
tigue at exercise levels below predicted peak may indi-
cate peripheral deconditioning [26] whereas dyspnoea as
the limiting symptom may be attributable to decreased
chest wall compliance caused by diffuse pleural thicken-
ing [5]. These findings differ from a study in people with
idiopathic pulmonary fibrosis (IPF), which reported that
35% of participants stopped exercise due to leg fatigue
and 65% due to dyspnoea [27]. This difference is likely
due to greater disease severity in the IPF group com-
pared to the people with ARPD, but also may be attrib-
utable to the slightly older age of our participants. The
higher prevalence of leg fatigue may be associated with
skeletal muscle changes attributable to aging [28],E between ICT and 6MWT
n (SD) Mean difference (95%CI) p
5) 21 (14 to 28) <0.001
3 (2 to 4) <0.001
4 (3 to 5) <0.001
CI = confidence interval; PR = pulse rate; b/min = beats per minute; RPE = rate
Figure 2 Pulse rate response during the 6MWT. PR = pulse rate;
bpm = beats per minute; Error bars = Standard error.
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onset of leg fatigue.
Health-related quality of life was reduced in people
with ARPD as measured by the SGRQ domains. Despite
these reductions, people with ARPD had higher levels of
HRQoL than reported in people with IPF [29] and
COPD [30]. To our knowledge, this is the first study to
demonstrate that people with ARPD experience reduc-
tions in HRQoL.
In people with ARPD we have demonstrated a moder-
ate relationship between 6MWD and peak work rate, al-
though weaker than relationships in COPD (r=0.63,
p<0.002; r=0.75, p<0.001)) [31,32]. We have also demon-
strated a moderate relationship between 6MWD and
VO2peak (ml/kg/min), although weaker than in end-
stage lung diseases (r=0.73, p<0.001) [33]. This is likely
due to the lesser disease severity in our participants.
Despite this, the relationship between 6MWD and peak
exercise capacity suggests that the 6MWT may be a use-
ful surrogate measure of peak exercise capacity in peopleTable 4 Relationships between 6MWD or peak work rate
and HRQoL scores, pulmonary function tests and
measures of physical activity (r-values)
Variable ARPD n=25
6MWD Peak work rate
FVC, % pred 0.52† 0.59†
DLCO, % pred 0.50
‡ 0.64*
Daily steps 0.38 0.24
Daily METs 0.45‡ 0.22
Daily energy expenditure 0.06 0.25
SGRQ Total −0.57† −0.71*
SGRQ Activity −0.50 ‡ −0.70*
*p <0.001, †p <0.01, ‡p<0.05.
ARPD = asbestos related pleural disease; n = number; 6MWD = six-minute walk
distance; FVC = forced vital capacity; % pred = percentage of predicted value;
DLCO = diffusing capacity for carbon monoxide; METs = metabolic equivalent;
SGRQ = St George’s Respiratory Questionnaire.with ARPD when cardiopulmonary exercise testing is
unavailable.
The 6MWT correlated moderately with the SGRQ
Total score and the SGRQ Activity domain score, similar
to relationships reported in COPD and interstitial lung
disease [24,29]. This suggests the impact of ARPD on
HRQoL may be reflected by the SGRQ, a questionnaire
originally designed for people with COPD.
Physical activity differs from exercise capacity. Higher
levels of daily physical activity have health benefits for
people with COPD [34] or coronary artery disease [35].
Conversely, reduced physical activity is related to
increased morbidity and mortality in COPD [11]. In this
study, the 6MWD correlated more strongly with daily
METs than did peak work rate, demonstrating the
6MWD may better reflect daily physical activity than a
peak exercise test. This is likely the consequence of daily
activities being performed at sub-maximal levels of in-
tensity, rather than maximal levels of intensity [18]. In
the absence of activity monitors in the clinical setting,
the 6MWT may be a useful surrogate measure of phys-
ical activity.
There was a significant increase in distance walked be-
tween the first and second 6MWT of 13 metres or 3%, a
smaller increase than reported in COPD [36] and inter-
stitial lung disease [9]. In COPD, two 6MWTs are
recommended to obtain an accurate measure of func-
tional exercise capacity. The small increase in distance
walked in the second 6MWT in people with ARPD
questions whether repeat testing is clinically important
in this population. However, functional exercise capacity
may be underestimated if a second test is not
performed.
Participants demonstrated a greater arterial oxyhaemo-
globin desaturation during the 6MWT compared to the
ICT, similar to people with COPD, and related to the
larger exercising muscle mass utilised during the 6MWT
[31]. We have demonstrated a peak cycle test is not
required to examine arterial oxyhaemoglobin desatur-
ation in people with ARPD and the 6MWT may provide
valuable and unique information on oxygen desaturation
during exercise.
The development of ARPD is often characterized by a
long latency period from exposure to dust to develop-
ment of disease [37]. As a result, the mean age of parti-
cipants was 71 years. With increasing age, the FEV1/
FVC ratio is known to decrease and the FEV1/FVC ratio
in our participants was within the range of predicted
normal values for people of this age [14].
This study has some limitations. No data were col-
lected on the metabolic and ventilatory responses to the
6MWT so no direct comparisons can be made for these
outcomes with the ICT. People on long term oxygen
therapy were excluded so the findings of this study
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clude people if they had a smoking history as this would
be unrepresentative of the patient population. Finally, we
did not have a group of healthy aged-matched controls
upon which a statistical comparison could be made,
however data were compared to previously published
predicted values for functional and peak exercise
capacity.
Conclusions
This is the first investigation of the effect of ARPD on
functional exercise capacity, demonstrating that this
population has reduced functional exercise capacity
measured by the 6MWT. This study has also established
that people with ARPD have reduced HRQoL. Further-
more, we have shown the 6MWD correlated with peak
exercise capacity, HRQoL and physical activity. The
6MWT would be a simple test to perform and integrate
into clinical practice to determine functional exercise
capacity in people with ARPD and may be a useful sur-
rogate measure of peak exercise capacity and physical
activity in the absence of cardiopulmonary exercise test-
ing and activity monitors. With few treatment options
available for people with ARPD, research is required to
address whether the impairments of reduced exercise
capacity and HRQoL are amenable to pulmonary
rehabilitation.
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